March 19, 2012 – Migdal HaEmeq. Enzymotec, a dynamic, biotech company and a leading global supplier of lipid-based products, is pleased to announce the opening of its Shanghai office. The new branch of Enzymotec is aimed at supporting the company's growing business activities in China as well as providing its existing customers with expert, on-hand customer service.
With a foothold in over 40 countries, Enzymotec develops and manufactures lipid-based biofunctional and nutraceutical ingredients and end products that are based on sophisticated proprietary technologies.
"This is a significant step forward for Enzymotec, which has successfully expanded its commercial activities over the last few years," says Dr. Ariel Katz, CEO of Enzymotec. "South East Asia in general and China in particular have become key markets for us due to the economic developments in the region. In addition, we believe that maintaining a local presence is highly important and fits our global marketing strategy."
Enzymotec's innovative solutions are divided into three business segments:
Infant Nutrition Division – Producer of InFatTM, a clinically-proven ingredient in infant formulas that mimics the fat of human milk. InFatTM is marketed through Advanced Lipids AB, a joint venture of AAK and Enzymotec. Advanced Lipids is a primary supplier of fat ingredients for leading infant formulas in China.
Bioactive Division – A major provider of lipid-based products providing high quality solutions for the body and mind.
VAYA Pharma– A researched-based, specialty pharmaceutical division dedicated to the discovery, development, manufacturing and marketing of innovative and effective, clinically tested and safe natural lipid-based medicines.
For more information visit our website: http://www.enzymotec.com/infant_nutrition/
Contact Details – Enzymotec
Global: [email protected]